Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth J Smith

Showing results (191-200 of 288) with videos related to

Pageof 29
Sort By:
Journal of the National Medical Association|June 8, 2019
Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.SMary Patricia Nowalk, Angela R Wateska, Chyongchiou Jeng Lin, et al.
American Journal of Preventive Medicine|June 21, 2021
Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. SeniorsKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Journal of Graduate Medical Education|October 28, 2017
High-Value Consults: A Curriculum to Promote Point-of-Care, Evidence-Based RecommendationsDeepa Rani Nandiwada, Amar Kohli, Megan McNamara, et al.
American Journal of Preventive Medicine|February 13, 2016
Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.SKenneth J Smith, Jonathan M Raviotta, Jay V DePasse, et al.
American Journal of Preventive Medicine|November 30, 2024
Cost-Effectiveness and Public Health Impact of 24-Valent Pneumococcal Conjugate Vaccine Compared With the Recommended Pneumococcal Vaccines in Older AdultsKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Journal of the American Geriatrics Society|February 23, 2020
Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older PopulationsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
American Journal of Preventive Medicine|February 1, 2020
Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. PopulationsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Neuropathology and Applied Neurobiology|December 15, 2022
Oxygen treatment reduces neurological deficits and demyelination in two animal models of multiple sclerosisMario Amatruda, Kate Harris, Alina Matis, et al.
Vaccine|June 25, 2021
Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysisKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Journal of Community Health|August 12, 2019
Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 YearsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Pageof 29

Showing results (191-200 of 288) with videos related to

Sort By:
Pageof 29
Journal of the National Medical Association|June 8, 2019
Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.SMary Patricia Nowalk, Angela R Wateska, Chyongchiou Jeng Lin, et al.
American Journal of Preventive Medicine|June 21, 2021
Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. SeniorsKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Journal of Graduate Medical Education|October 28, 2017
High-Value Consults: A Curriculum to Promote Point-of-Care, Evidence-Based RecommendationsDeepa Rani Nandiwada, Amar Kohli, Megan McNamara, et al.
American Journal of Preventive Medicine|February 13, 2016
Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.SKenneth J Smith, Jonathan M Raviotta, Jay V DePasse, et al.
American Journal of Preventive Medicine|November 30, 2024
Cost-Effectiveness and Public Health Impact of 24-Valent Pneumococcal Conjugate Vaccine Compared With the Recommended Pneumococcal Vaccines in Older AdultsKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Journal of the American Geriatrics Society|February 23, 2020
Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older PopulationsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
American Journal of Preventive Medicine|February 1, 2020
Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. PopulationsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Neuropathology and Applied Neurobiology|December 15, 2022
Oxygen treatment reduces neurological deficits and demyelination in two animal models of multiple sclerosisMario Amatruda, Kate Harris, Alina Matis, et al.
Vaccine|June 25, 2021
Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysisKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Journal of Community Health|August 12, 2019
Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 YearsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Pageof 29